Research programme: friulimicin B analogues - UniQuest
Latest Information Update: 28 Sep 2020
At a glance
- Originator University of Queensland
- Developer UniQuest; University of Queensland
- Class Anti-infectives; Antibacterials; Lipopeptides; Small molecules
- Mechanism of Action Bacterial polysaccharide inhibitors; Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Gram-positive infections; Respiratory tract infections
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Gram-positive-infections in Australia
- 28 Sep 2020 No recent reports of development identified for preclinical development in Respiratory-tract-infections in Australia
- 03 Aug 2016 Research programme: friulimicin B analogues - UniQuest is available for licensing -http://uniquest.com.au/filething/get/12065/Fruilimicin-B%20Analogues%20for%20Gram-positive%20Bacteria%20UniQuest.pdf